GlassScriptPhysician profile
Gary Kao
NPI 1346582095
$25,168.39
in general payments reported to CMS, 2019-2025
43 companies · $1,663 in 2025
The $1,663 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $1,517 · 2021: $1,269 · 2022: $6,444 · 2023: $8,827 · 2024: $4,763 · 2025: $1,663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $3,870 · Entertainment: $32.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,350.50 |
| Travel and Lodging | $3,869.71 |
| Entertainment | $32.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,861.98 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Superion Indirect Decompression System |
| Nalu Medical, INC. | $4,086.13 | 2021-2025 | Nalu Neurostimulation System |
| Medtronic, INC. | $2,691.10 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Spinal Simplicity, LLC | $2,276.26 | 2023-2025 | Ha Minuteman G3-R |
| Vertos Medical, INC. | $1,828.42 | 2022-2024 | Mild Device Kit |
| Painteq LLC | $1,271.10 | 2022-2024 | Painteq |
| Genesys Orthopedics Systems, L.L.C. | $1,211.15 | 2022 | |
| Relievant Medsystems, INC. | $1,021.80 | 2023 | Intracept |
| Foundation Fusion Solutions, LLC | $838.66 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $642.47 | 2019-2025 | Xtampza, Belbuca |
| Spr Therapeutics, INC | $572.24 | 2022-2025 | Sprint Pns System |
| Abbott Laboratories | $465.34 | 2021-2024 | Proclaim, Eterna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $460.83 | 2021-2025 | Relistor |
| Biotronik Nro, INC. | $450.71 | 2025 | Prospera |
| Centinel Spine, LLC | $271.84 | 2019-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $239.17 | 2022-2024 | |
| Stimwave Technologies Incorporated | $202.69 | 2019-2022 | |
| Lilly USA, LLC | $176.05 | 2021-2024 | Emgality |
| Ferring Pharmaceuticals INC. | $171.26 | 2022-2024 | Euflexxa |
| Biodelivery Sciences International, INC. | $157.44 | 2021 | |
| Si-Bone, INC. | $142.77 | 2019-2023 | |
| Nevro Corp. | $109.09 | 2022 | |
| Amgen INC. | $104.07 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $102.93 | 2022 | |
| Almatica Pharma LLC | $96.29 | 2022-2023 | Gralise |
| Tersera Therapeutics LLC | $86.74 | 2023-2024 | Prialt |
| Teva Pharmaceuticals USA, INC. | $80.62 | 2019-2020 | |
| Forte Bio-Pharma LLC | $69.06 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Saluda Medical Americas, INC. | $68.52 | 2023 | Evoke Scs |
| Alevio, LLC | $63.15 | 2023 | Sicure Sacroiliac Joint Fusion System |
| Clarius Mobile Health Corp. | $50.00 | 2021 | |
| Averitas Pharma INC. | $46.24 | 2025 | Qutenza |
| Biohaven Pharmaceuticals, INC. | $43.26 | 2021 | |
| Curonix LLC | $37.36 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Bioventus LLC | $26.67 | 2025 | Durolane |
| Azurity Pharmaceuticals, INC. | $24.49 | 2023 | Horizant |
| Pfizer INC. | $23.04 | 2023 | |
| Orthogenrx INC. | $19.70 | 2021 | |
| Valinor Pharma, LLC | $18.52 | 2024 | Movantik |
| Idorsia Pharmaceuticals US INC | $17.40 | 2023 | Quviviq |
| Amneal Pharmaceuticals LLC | $15.71 | 2023 | Lyvispah |
| Scilex Pharmaceuticals INC. | $14.61 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Kao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.